TGF‐β antagonist attenuates fibrosis but not luminal narrowing in experimental tracheal stenosis

Antón‐Pacheco, Juan L.; Usategui, Alicia; Martínez, Iván; García-Herrero, Carmen M.; Gámez, Antonio; Grau, Montserrat; Martı́nez, Ana M.; Rodríguez‐Peralto, José Luis; Pablos, José L.

doi:10.1002/lary.26402

Cited by 14 publications

(18 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Induced myofibroblasts increase fibrotic markers, such as stress fiber, α‐smooth muscle actin (α‐SMA) and collagen . Research has shown that TGF‐β1 antagonistic antibodies represent antifibrotic activity in various experimental models of fibrosis . Therefore, TGF‐β1 is a potential therapeutic target in fibrotic conditions.…”

Section: Introductionmentioning

confidence: 99%

Combined treatment of low‐level laser therapy and phloroglucinol for inhibition of fibrosis

et al. 2019

View full text Add to dashboard Cite

Background and Objectives Fibrosis is a highly prevalent disease, which is responsible for 45% of deaths through pathological effects in developed countries. Previous studies have reported that low‐level laser therapy (LLLT) can modulate fibrotic activity, but significant enhancement of therapeutic efficacy is still required for clinical translation. The aim of this study is to evaluate the feasible effect of LLLT combined with phloroglucinol (PHL) on the inhibition of fibrosis in vitro. Study Design/Materials and Methods NIH/3T3 murine embryonic fibroblasts cells were cultured and transforming growth factor‐β1 (TGF‐β1) was treated for transition of fibroblasts. After TGF‐β1 treatment, LLLT and PHL were used, respectively, and in combination to suppress fibrosis. 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide and BrdU assays were performed to estimate the cell viability and proliferation. To evaluate the expression of fibrotic markers, we used confocal immunofluorescence and western blot. Results When compared with respectively treated groups, the group with the combined treatment of LLLT and PHL significantly reduced cell viability and proliferation. Immunofluorescence staining showed that the combined group minimized more α‐smooth muscle actin (α‐SMA) and type I collagen than the other groups. Western blot analysis showed that the combined treatment had significant decreases in α‐SMA, TGF‐β1, and type I collagen. Conclusions PHL‐assisted LLLT may be an effective treatment to inhibit fibrosis due to its additive effects. The combined treatment has a potential to be an alternative treatment for fibrosis. Lasers Surg. Med. © 2019 Wiley Periodicals, Inc.

show abstract

Section: Introductionmentioning

confidence: 99%

Combined treatment of low‐level laser therapy and phloroglucinol for inhibition of fibrosis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Most previous studies that have developed animal models of airway stenosis have used an open approach. Authors have induced airway injury with a wide variety of methods, including brushing of the trachea, the use of the carbon‐dioxide laser, the application of silver nitrate or hydrochloric acid to the airway mucosa, and cautery . Balloon dilation is frequently used for the management of SGS; however, this modality disrupts scar tissue through radial high‐pressure force and may fracture the cricoid cartilage, depending on balloon size and pressure.…”

Section: Discussionmentioning

confidence: 99%

“…A wide array of methods for inducing airway stenosis in animal models has been described, including intubation only, brushing, application of silver nitrate or hydrochloric acid, use of electrocautery, and use of the carbon‐dioxide laser . Previous authors have not, however, consistently assessed the postinjury endoscopic appearance of the airway, postinjury respiratory symptoms, and histologic findings.…”

Section: Introductionmentioning

confidence: 99%

“…Previous authors have not, however, consistently assessed the postinjury endoscopic appearance of the airway, postinjury respiratory symptoms, and histologic findings. In addition, most previous animal models with induced SGS have involved open approaches . These approaches disrupt the cricoid cartilage, making it difficult to further assess the outcomes of balloon dilation—a management approach that has steadily gained favor in many pediatric institutions.…”

Section: Introductionmentioning

confidence: 99%

“…With these collective issues in mind, the aim of our study was to create a reproducible survival animal model for acute airway stenosis using an endoscopic approach and to document this model symptomatically, endoscopically, and histologically. Given the previous research demonstrating that New Zealand white rabbits provide a reliable model for studying airway stenosis, we used these animals to develop our model.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Development of a survival animal model for subglottic stenosis

Schweiger¹,

Hart

Tabangin

et al. 2018

The Laryngoscope

View full text Add to dashboard Cite

show abstract

Establishing an Endoscopic Chronic Subglottic Stenosis Rabbit Model

et al. 2021

View full text Add to dashboard Cite

Objectives/Hypothesis To develop a reproducible and consistent chronic subglottic stenosis (SGS) in an endoscopic animal model. Study Design Prospective study. Methods We conducted a prospective study using New Zealand white rabbits. Chronic SGS was induced endoscopically by Bugbee electrocautery to 50% to 75% of the subglottic area's circumference, followed by 4‐hour endotracheal intubation. The rabbit airways were endoscopically assessed and sized with uncuffed endotracheal tubes (ETTs) before the injury, during follow‐up, and at the endpoints. There were four endpoints: 2, 4, 6, and 8 weeks post SGS induction. Animals were humanely euthanized for histopathological examination of the subglottic injury site and microscopic measurement of the cricoid lumen. Results Twenty‐two rabbits reached the endpoints, and 18 rabbits developed chronic SGS. ETT size significantly decreased by 0.5 from preinjury to the endpoint in all groups, P < .001. Control median cricoid lumen measurements were 20.48 mm2, the median cricoid lumen measurement for the 2 weeks endpoint was 14.3 mm2, 4 weeks 11.69 mm2, 6 weeks 16.03 mm2, and 8 weeks endpoint median was 16.33 mm2. Histopathological examination showed chronic scar tissue and new cartilage formation at the cricoid level, mainly at the posterior subglottic injury site starting from 4 weeks postinjury. Collagen staining revealed substantial amounts of organized collagen and different collagen orientation starting 4 weeks postinjury lasting until 8 weeks postinjury. Conclusion We developed an animal model to study chronic SGS. This model will be utilized to compare different endoscopic treatment interventions in acute SGS versus chronic SGS and further define the molecular basis of SGS. Level of Evidence NA Laryngoscope, 132:1909–1915, 2022

show abstract

TGF‐β antagonist attenuates fibrosis but not luminal narrowing in experimental tracheal stenosis

Abstract: NA. Laryngoscope, 127:561-567, 2017.

Cited by 14 publications

References 41 publications

Combined treatment of low‐level laser therapy and phloroglucinol for inhibition of fibrosis

Combined treatment of low‐level laser therapy and phloroglucinol for inhibition of fibrosis

Development of a survival animal model for subglottic stenosis

Establishing an Endoscopic Chronic Subglottic Stenosis Rabbit Model

Contact Info

Product

Resources

About